Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ono Pharma USA Inc
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female subjects age 18-80 (inclusive) with confirmed diagnosis of OHT or OAG
Confirmed diagnosis of bilateral OHT or chronic open-angle glaucoma
Able to undergo washout of all ocular drugs
An IOP ≥ 22mmHg at 8:00 AM and ≥ 21 mmHg at 10:00 AM in at least one eye; but ≤ 35 mmHg at all time points in both eyes on Day -2 and Day -1
Central corneal thickness 500-600 µm at screening in both eyes
BCVA 20/100 or better in both eyes
You may not be if
Any history of severe ocular trauma in either eye at any time
Any history of previous intraocular or ocular laser surgery within the past 3 months or any refractive surgery procedure within the past 6 months of screening visit in the study eye(s)
Cataracts that prevent observation of the fundus in either eye
Clareo Health | Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma
